MedTrace Logo

A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nuclear Extract

NCT06795945 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-12-10

No results posted yet for this study

Summary

The goal of this trial is to find out if Thymus Nuclear Extract is safe and well-tolerated in healthy men and women by testing three different dose levels and comparing the results to a placebo.

Conditions

Interventions

DIETARY_SUPPLEMENT

TPG1

* Thymus Nuclear Extract Dose 1 (860 mg \[2 tablets, 2x/day; total 4 tablets per day\]) * Placebo (6 tablets, 2x/day; total 12 tablets per day)

DIETARY_SUPPLEMENT

TPG2

* Thymus Nuclear Extract Dose 2 (2150 mg \[5 tablets, 2x/day; total 10 tablets per day\]) * Placebo (3 tablets, 2x/day; total 6 tablets per day)

DIETARY_SUPPLEMENT

TPG3

Thymus Nuclear Extract Dose 3 (3440 mg \[8 tablets, 2x/day; total 16 tablets per day\])

DIETARY_SUPPLEMENT

Placebo

Placebo (8 tablets, 2x/day; total 16 tablets per day)

Sponsors & Collaborators

  • Nutrasource Pharmaceutical and Nutraceutical Services, Inc.

    collaborator NETWORK

  • Standard Process Inc.

    lead INDUSTRY

Principal Investigators

  • Bassem F. El-Khodor, PHD · Standard Process Inc.

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-02-04
Primary Completion
2025-11-24
Completion
2025-11-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06795945 on ClinicalTrials.gov